418 related articles for article (PubMed ID: 27893699)
1. Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient.
Abe J; Sato T; Tanaka R; Okazaki T; Takahashi S
Am J Case Rep; 2016 Nov; 17():880-882. PubMed ID: 27893699
[TBL] [Abstract][Full Text] [Related]
2. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
6. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
7. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.
Yasuda Y; Urata Y; Tohnai R; Ito S; Kawa Y; Kono Y; Hattori Y; Tsuda M; Sakuma T; Negoro S; Satouchi M
Intern Med; 2018 May; 57(9):1269-1272. PubMed ID: 29279482
[TBL] [Abstract][Full Text] [Related]
8. Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.
Pluchart H; Pinsolle J; Cohen J; Ferretti GR; Bedouch P; Giaj Levra M; Toffart AC; Moro-Sibilot D
J Med Case Rep; 2017 Jul; 11(1):183. PubMed ID: 28679408
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of Advanced or Postoperative Recurrent Non-small Lung Cancer Cases Treated with Nivolumab].
Ichiki Y; Iwanami T; Kakizoe K; Hamatsu T; Suehiro T; Yoneda K; Tanaka F; Sugimachi K
J UOEH; 2017; 39(4):291-297. PubMed ID: 29249742
[TBL] [Abstract][Full Text] [Related]
10. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
12. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.
Läubli H; Hench J; Stanczak M; Heijnen I; Papachristofilou A; Frank S; Zippelius A; Stenner-Liewen F
J Immunother Cancer; 2017; 5():46. PubMed ID: 28642817
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
Richard K; Weslow J; Porcella SL; Nanjappa S
Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
[TBL] [Abstract][Full Text] [Related]
15. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
16. Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
Raskin J; Masrori P; Cant A; Snoeckx A; Hiddinga B; Kohl S; Janssens A; Cras P; Van Meerbeeck JP
Lung Cancer; 2017 Jul; 109():74-77. PubMed ID: 28577954
[TBL] [Abstract][Full Text] [Related]
17. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
19. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
20. The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.
Ochi M; Miyamoto S; Terada Y; Furuhata Y; Awano N; Izumo T; Ikushima S; Bae Y; Kumasaka T; Kunito H
Intern Med; 2018 Jun; 57(12):1773-1777. PubMed ID: 29434118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]